PAHC · Phibro Animal Health Corporatio
$34.03
+3.21% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$2B
Trailing P/E
15.1
Forward P/E
10.5
Dividend yield
1.0%
Beta
0.46
Avg volume
0M
Employees
2K
2D change
—
5D change
3.53%
10D change
5.79%
30D change
11.20%
60D change
14.94%
MTD change
9.78%
YTD change
-5.06%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PAHC
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-14
Latest call per bank · past 12 months
Citigroup
Neutral$44.00
+29.3% vs priceJP Morgan
Overweight$50.00
+46.9% vs priceBank of America
Underperform$27.00
-20.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-14 | Citigroup | Maintains | Neutral | $62.00 → $44.00 |
| 2026-04-15 | Citigroup | Initiates | Neutral | $0.00 → $62.00 |
| 2025-11-07 | JP Morgan | Maintains | Overweight | $45.00 → $50.00 |
| 2025-08-29 | Bank of America | Maintains | Underperform | $19.00 → $27.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 64 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.5% above the 50-day MA ($32.61).
- Price vs 200-day MA: Trading 14.3% below the 200-day MA ($42.42).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.44) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($25.79) and high ($59.33).
PAHC Price Chart
Loading chart for PAHC…
Fundamentals
About Phibro Animal Health Corporatio
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.